
Biosimilars: Unlocking access, closing the cost divide
Newsletters and Deep Dive digital magazine
GSK decided to abandon a TIGIT-targeted drug for cancer this week, then hatched a plan to replace it with a candidate for liver disease MASH.
Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.
Every breakthrough in medicine, every new treatment that changes lives, starts with research.
The importance of biosimilars only continues to grow, driven by the potential savings they are able to deliver to healthcare systems.
A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
Developments in the oncology space in 2024 brought hope to both industry and patients.
Improving Global Access to Life-Changing Therapeutics...
The ESG in Life Sciences Summit West is coming to San Francisco! (July 8-10, 2025).